Ranked #5,766 of 8,699 institutional investors
Enavate Sciences GP, LLC
New York, NY
$231M
US stock portfolio at live prices · today −$1.6M (−0.67%)
Market closed. Prices as of Nov 20, 6:11 AM ET
- Value at quarter end (Q3 2026)
- $280M
- Change from Q2 2026
- −$65.6M (−19.00%)
- Positions
- 8 · 1 new, 0 sold out
- Filed
- Nov 16, 2026
Holdings
Q3 2026 13F, live pricesZBIO 31.7%BRVE 30.7%IMNM 26.0%SION 3.19%CMPX 2.29%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| ZBIO Zenas BioPharma, Inc. | 2,919,159 | $73.1M | 31.7% | Reduced −26% |
| BRVE Braveheart Bio, Inc. | 3,674,656 | $70.8M | 30.7% | New |
| IMNM Immunome, Inc. | 3,613,799 | $60.0M | 26.0% | Unchanged |
| SION Sionna Therapeutics, Inc. | 2,478,030 | $7.4M | 3.19% | Unchanged |
| CMPX Compass Therapeutics, Inc. | 7,788,150 | $5.3M | 2.29% | Unchanged |
| UPB Upstream Bio, Inc. | 2,459,703 | $4.9M | 2.13% | Unchanged |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 2,626,946 | $4.9M | 2.12% | Unchanged |
| CAMP Camp4 Therapeutics Corp | 1,041,127 | $4.2M | 1.81% | Reduced −27% |